QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
Log in
NASDAQ:ONCY

Oncolytics Biotech Stock Forecast, Price & News

$1.64
-0.02 (-1.20 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.56
Now: $1.64
$1.70
50-Day Range
$1.58
MA: $1.74
$1.99
52-Week Range
$0.35
Now: $1.64
$6.02
Volume226,156 shs
Average Volume873,269 shs
Market Capitalization$69.05 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCY
CUSIPN/A
CIKN/A
Phone403-670-7377

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-24,960,000.00

Miscellaneous

EmployeesN/A
Market Cap$69.05 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$1.64
-0.02 (-1.20 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONCY News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oncolytics Biotech (NASDAQ:ONCY) Frequently Asked Questions

How has Oncolytics Biotech's stock been impacted by COVID-19?

Oncolytics Biotech's stock was trading at $1.74 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ONCY stock has decreased by 5.7% and is now trading at $1.64.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Oncolytics Biotech?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Oncolytics Biotech
.

When is Oncolytics Biotech's next earnings date?

Oncolytics Biotech is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Oncolytics Biotech
.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech, Inc. (NASDAQ:ONCY) issued its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.03.
View Oncolytics Biotech's earnings history
.

What price target have analysts set for ONCY?

4 Wall Street analysts have issued 12 month price objectives for Oncolytics Biotech's shares. Their forecasts range from $6.00 to $9.00. On average, they anticipate Oncolytics Biotech's stock price to reach $7.33 in the next year. This suggests a possible upside of 347.2% from the stock's current price.
View analysts' price targets for Oncolytics Biotech
.

Who are some of Oncolytics Biotech's key competitors?

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), OrganiGram (OGI), KushCo (KSHB), Pennsylvania R.E.I.T. (PEI), BioNano Genomics (BNGO), Cannabics Pharmaceuticals (CNBX), DHT (DHT) and Novan (NOVN).

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the following people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look, Chief Financial Officer
  • Mr. Michael Moore, VP of Investor Relations & Corp. Communications
  • Dr. Rita Laeufle, Chief Medical Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."

Who are Oncolytics Biotech's major shareholders?

Oncolytics Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.36%), Creative Planning (0.27%), Financial Consulate Inc. (0.10%), International Assets Investment Management LLC (0.08%) and Virtu Financial LLC (0.04%).

Which institutional investors are buying Oncolytics Biotech stock?

ONCY stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Financial Consulate Inc., International Assets Investment Management LLC, Creative Planning, and Virtu Financial LLC.

How do I buy shares of Oncolytics Biotech?

Shares of ONCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of ONCY stock can currently be purchased for approximately $1.64.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of $69.05 million. The company earns $-24,960,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

What is Oncolytics Biotech's official website?

The official website for Oncolytics Biotech is www.oncolyticsbiotech.com.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The company can be reached via phone at 403-670-7377 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.